# Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis

> **NCT06531122** · PHASE3 · RECRUITING · sponsor: **Kafrelsheikh University** · enrollment: 200 (estimated)

## Conditions studied

- Cerebral Venous Thrombosis

## Interventions

- **DRUG:** Apixaban 5MG
- **DRUG:** Rivaroxaban 20 MG Oral Tablet

## Key facts

- **NCT ID:** NCT06531122
- **Lead sponsor:** Kafrelsheikh University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2024-09-20
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06531122

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06531122, "Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06531122. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*